ArticleInternational journal of nanomedicine2015
Enhancement of radiotherapy by ceria nanoparticles modified with neogambogic acid in breast cancer cells.
Article in International journal of nanomedicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 56 citations in OpenAlex.
- Nanoparticle-Based Radiosensitization in Breast Cancer: A Multimodal Approach to Therapy and Immune Regulation.Biotechnology journal · 2026Review
- Periodic Table of Immunomodulatory Elements and Derived Two-Dimensional Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.Journal of nanobiotechnology · 2024Review
- Identification of natural compound garcinone E as a novel autophagic flux inhibitor with anticancer effect in nasopharyngeal carcinoma cells.Pharmaceutical biology · 2023Article
- Current advances in nanoformulations of therapeutic agents targeting tumor microenvironment to overcome drug resistance.Cancer metastasis reviews · 2023Review
- Caged Polyprenylated Xanthones inDrug design, development and therapy · 2023Review
- Advanced applications of cerium oxide based nanozymes in cancer.RSC advances · 2022Review
- A GdWMolecules (Basel, Switzerland) · 2021Article
- Internalized Nanoceria Modify the Radiation-Sensitivity Profile of MDA MB231 Breast Carcinoma Cells.Biology · 2021Article
- Cerium Oxide Nanoparticles: A New Therapeutic Tool in Liver Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- Mechanisms for Tuning Engineered Nanomaterials to Enhance Radiation Therapy of Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Review
- Ceria-Containing Hybrid Multilayered Microcapsules for Enhanced Cellular Internalisation with High Radioprotection Efficiency.Molecules (Basel, Switzerland) · 2020Article
- The Rational Design and Biological Mechanisms of Nanoradiosensitizers.Nanomaterials (Basel, Switzerland) · 2020Review
- Gambogenic acid exerts anticancer effects in cisplatin‑resistant non‑small cell lung cancer cells.Molecular medicine reports · 2020Article
- Chemical Mechanisms of Nanoparticle Radiosensitization and Radioprotection: A Review of Structure-Function Relationships Influencing Reactive Oxygen Species.International journal of molecular sciences · 2020Review
- Effects of Selenium Nanoparticles Combined With Radiotherapy on Lung Cancer Cells.Frontiers in bioengineering and biotechnology · 2020Article
- Targeting the unfolded protein response in head and neck and oral cavity cancers.Experimental cell research · 2019Review
- Layer-by-Layer Cerium Oxide Nanoparticle Coating for Antioxidant Protection of Encapsulated Beta Cells.Advanced healthcare materials · 2019Article
- Gambogenic acid inhibits the proliferation of small‑cell lung cancer cells by arresting the cell cycle and inducing apoptosis.Oncology reports · 2019Article
- Transcriptional Analysis of the Effects of Gambogic Acid and Neogambogic Acid on Methicillin-ResistantFrontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiotherapy is one of the main strategies for cancer treatment but has significant challenges, such as cancer cell resistance and radiation damage to normal tissue. Radiosensitizers that selectively increase the susceptibility of cancer cells to radiation can enhance the effectiveness of radiotherapy. We report here the development of a novel radiosensitizer consisting of monodispersed ceria nanoparticles (CNPs) covered with the anticancer drug neogambogic acid (NGA-CNPs). These were used in conjunction with radiation in MCF-7 breast cancer cells, and the efficacy and mechanisms of action of this combined treatment approach were evaluated. NGA-CNPs potentiated the toxic effects of radiation, leading to a higher rate of cell death than either treatment used alone and inducing the activation of autophagy and cell cycle arrest at the G2/M phase, while pretreatment with NGA or CNPs did not improve the rate of radiation-induced cancer cells death. However, NGA-CNPs decreased both endogenous and radiation-induced reactive oxygen species formation, unlike other nanomaterials. These results suggest that the adjunctive use of NGA-CNPs can increase the effectiveness of radiotherapy in breast cancer treatment by lowering the radiation doses required to kill cancer cells and thereby minimizing collateral damage to healthy adjacent tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.